Worth Watching: What’s in Retrophin Inc After Today’s Huge Increase?

Worth Watching: What's in Retrophin Inc After Today's Huge Increase?

The stock of Retrophin Inc (NASDAQ:RTRX) is a huge mover today! About 223,988 shares traded hands. Retrophin Inc (NASDAQ:RTRX) has risen 34.38% since April 14, 2016 and is uptrending. It has outperformed by 29.70% the S&P500.
The move comes after 5 months positive chart setup for the $807.40M company. It was reported on Nov, 16 by Barchart.com. We have $31.58 PT which if reached, will make NASDAQ:RTRX worth $379.48M more.

Retrophin Inc (NASDAQ:RTRX) Ratings Coverage

Out of 3 analysts covering Retrophin (NASDAQ:RTRX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Retrophin has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The rating was downgraded by Zacks to “Buy” on Wednesday, August 12. BMO Capital Markets initiated the shares of RTRX in a report on Tuesday, April 12 with “Outperform” rating. The firm has “Mkt Outperform” rating given on Monday, November 2 by JMP Securities.

According to Zacks Investment Research, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego.”

Insitutional Activity: The institutional sentiment increased to 1.3 in 2016 Q2. Its up 0.23, from 1.07 in 2016Q1. The ratio improved, as 15 funds sold all Retrophin Inc shares owned while 29 reduced positions. 12 funds bought stakes while 45 increased positions. They now own 38.66 million shares or 4.59% more from 36.97 million shares in 2016Q1.
Moreover, Tiaa Cref Investment Mgmt Ltd Limited Liability Company has 0% invested in Retrophin Inc (NASDAQ:RTRX) for 160,757 shares. Millennium Mgmt Ltd holds 0.03% or 776,294 shares in its portfolio. Schwab Charles Mgmt Inc accumulated 120,921 shares or 0% of the stock. Jefferies Group Inc Lc owns 59,995 shares or 0% of their US portfolio. Credit Suisse Ag owns 70,100 shares or 0% of their US portfolio. Pnc Finance Grp owns 163 shares or 0% of their US portfolio. Fin Architects Incorporated last reported 2,000 shares in the company. Park West Asset Limited Liability Corporation holds 800,000 shares or 1.44% of its portfolio. Moreover, Consonance Lp has 6.81% invested in Retrophin Inc (NASDAQ:RTRX) for 2.70M shares. Blackrock Gru Limited has invested 0% of its portfolio in Retrophin Inc (NASDAQ:RTRX). Everpoint Asset Mgmt Llc last reported 0.19% of its portfolio in the stock. Northern Tru has 0% invested in the company for 379,439 shares. Price T Rowe Md last reported 0% of its portfolio in the stock. Teacher Retirement System Of Texas reported 4,434 shares or 0% of all its holdings. Dekabank Deutsche Girozentrale has invested 0% of its portfolio in Retrophin Inc (NASDAQ:RTRX).

Insider Transactions: Since June 1, 2016, the stock had 0 insider purchases, and 2 selling transactions for $297,343 net activity. 8,750 shares were sold by Shih Alvin, worth $142,059 on Thursday, September 1.

More recent Retrophin Inc (NASDAQ:RTRX) news were published by: Fool.com which released: “Why Shares of Retrophin Inc Are Soaring Today” on September 07, 2016. Also Fool.com published the news titled: “Why Retrophin Inc was Down Today” on February 10, 2016. Reuters.com‘s news article titled: “Retrophin to pay $3 million in US lawsuit over Shkreli’s tenure” with publication date: February 03, 2016 was also an interesting one.

RTRX Company Profile

Retrophin, Inc. (Retrophin), incorporated on February 7, 2008, is a biopharmaceutical company. The Firm is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Firm sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). The Company’s Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. The Company’s Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. The Company’s Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment